[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622064":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":30,"studyPopulation":30,"armGroups":37,"interventions":50,"overallOfficials":60,"centralContacts":64,"locations":70,"responsibleParty":127,"collaborators":30,"id":129,"slug":30,"hasResults":130,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":130,"sex":136,"minAge":137,"maxAge":30,"enrollmentInfo":138,"targetDuration":30,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":152,"whyStopped":30,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":30},[9],{"measure":10,"description":11,"timeFrame":12},"Improvement of at least 25% in liver function tests on day 21 after randomization","The rate of patients showing an improvement of at least 25% in liver function tests (alkaline phosphatase and\u002For gamma-GT) on Day 21 after randomization.","21 days after randomization",[14,18,22,26],{"measure":15,"description":16,"timeFrame":17},"Rate of Hepatitis Resolution at 6 Months","Rate of patients with resolution of hepatitis, defined as hepatitis grade ≤ 1 according to the current National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), at 6 months after randomization.","6 Months after randomization",{"measure":19,"description":20,"timeFrame":21},"Time to Hepatitis Resolution","Time to hepatitis resolution, defined as the time from the date of randomization to the date of hepatitis resolution (grade ≤ 1). Hepatitis severity will be graded according to the current National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)","From Randomization to end of follow-up at 12 months",{"measure":23,"description":24,"timeFrame":25},"Tolerance to UDCA and\u002For Corticosteroids","Tolerance to ursodeoxycholic acid (UDCA) and\u002For corticosteroids will be evaluated through the assessment of adverse events. Adverse events will be collected throughout the study and graded according to the current National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)","From treatment initiation following the randomization to end of follow-up at 12 months",{"measure":27,"description":28,"timeFrame":29},"Resumption of immunotherapy","Rate of patients in whom resumption of immunotherapy was possible after hepatitis within 12 months after randomization","Within 12 months after randomization",null,{"allocation":32,"interventionModel":33,"interventionModelDescription":30,"primaryPurpose":34,"observationalModel":30,"timePerspective":30,"maskingInfo":35},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":36,"maskingDescription":30,"whoMasked":30},"NONE",[38,44],{"label":39,"type":40,"description":41,"interventionNames":42},"Experimental arm","EXPERIMENTAL","Patients randomized to the experimental arm will receive ursodeoxycholic acid (UDCA) as initial treatment for hepatitis. After evaluation of the primary endpoint at Day 21, UDCA treatment will be continued for a total duration of 6 months. In case of lack of response to UDCA, patients will continue UDCA and will additionally receive corticosteroids which represent the reference treatment.",[43],"Drug: UDCA (Ursodeoxycholic acid)",{"label":45,"type":46,"description":47,"interventionNames":48},"Control arm","ACTIVE_COMPARATOR","Patients randomized to the control arm will receive the reference treatment, corticosteroids. Corticosteroids will be given at a dose of 0.5-1 mg\u002Fkg\u002Fday for 21 days, followed by tapering in weekly steps of 10 mg until treatment discontinuation. At Day 21, in case of lack of treatment response, defined as no decrease of alkaline phosphatase and\u002For gamma-glutamyl transferase levels of at least 25% compared with baseline, corticosteroid tapering will continue, and ursodeoxycholic acid (UDCA) will be added at a dose of 13-15 mg\u002Fkg\u002Fday.",[49],"Drug: Corticosteroids (Reference Treatment)",[51,56],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":30},"DRUG","UDCA (Ursodeoxycholic acid)","Ursodeoxycholic acid (UDCA) will be administered orally at an initial dose of 13-15 mg\u002Fkg\u002Fday, divided into two daily doses. After assessment of the primary endpoint at Day 21, UDCA will be continued for a total treatment duration of 6 months. In case of absence of treatment response, defined as no decrease of alkaline phosphatase and\u002For gamma-glutamyl transferase levels of at least 25% compared with baseline, corticosteroids which represent the reference treatment, will be added at a dose of 0.5-1 mg\u002Fkg.",[39],{"type":52,"name":57,"description":58,"armGroupLabels":59,"otherNames":30},"Corticosteroids (Reference Treatment)","Corticosteroids will be administered orally at a dose of 0.5-1 mg\u002Fkg\u002Fday for 21 days, followed by a tapering schedule of 10 mg per week until treatment discontinuation. At Day 21, if there is no adequate response (defined as less than 25% decrease in alkaline phosphatase and\u002For gamma-glutamyl transferase from baseline), the corticosteroid taper will continue and ursodeoxycholic acid (UDCA) will be added at a dose of 13-15 mg\u002Fkg\u002Fday.",[45],[61],{"name":62,"affiliation":5,"role":63},"Dr. Meunier","PRINCIPAL_INVESTIGATOR",[65],{"name":66,"role":67,"phone":68,"phoneExt":30,"email":69},"Dr. MEUNIER","CONTACT","+33467330224","lucy.meunier@chu-montpellier.fr",[71,85,93,103,111,119],{"facility":72,"status":30,"city":73,"state":30,"zip":30,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"CHU Bordeaux","Bordeaux","France","FR",{"type":77,"coordinates":78},"Point",[79,80],-0.58046,44.84124,{"lat":80,"lon":79},[83],{"name":84,"role":67,"phone":30,"phoneExt":30,"email":30},"Dr. CHERMAK",{"facility":86,"status":30,"city":87,"state":30,"zip":30,"country":74,"countryCode":75,"cosmosGeoPoint":88,"geoPoint":92,"contacts":30},"HCL Croix Rousse","Lyon",{"type":77,"coordinates":89},[90,91],4.84789,45.74906,{"lat":91,"lon":90},{"facility":94,"status":30,"city":95,"state":30,"zip":30,"country":74,"countryCode":75,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"CHU Montpellier","Montpellier",{"type":77,"coordinates":97},[98,99],3.87635,43.61093,{"lat":99,"lon":98},[102],{"name":66,"role":67,"phone":68,"phoneExt":30,"email":69},{"facility":104,"status":30,"city":105,"state":30,"zip":30,"country":74,"countryCode":75,"cosmosGeoPoint":106,"geoPoint":110,"contacts":30},"APHP Paul Brousse","Paris",{"type":77,"coordinates":107},[108,109],2.3488,48.85341,{"lat":109,"lon":108},{"facility":112,"status":30,"city":113,"state":30,"zip":30,"country":74,"countryCode":75,"cosmosGeoPoint":114,"geoPoint":118,"contacts":30},"CHU Poitiers","Poitiers",{"type":77,"coordinates":115},[116,117],0.34348,46.58261,{"lat":117,"lon":116},{"facility":120,"status":30,"city":121,"state":30,"zip":30,"country":74,"countryCode":75,"cosmosGeoPoint":122,"geoPoint":126,"contacts":30},"CHU Toulouse","Toulouse",{"type":77,"coordinates":123},[124,125],1.44367,43.60426,{"lat":125,"lon":124},{"type":128,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100622064",false,"NCT07378761","Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis","Efficacy of Ursodeoxycholic Acid Versus Corticosteroids for the Treatment of Cholestatic Hepatitis Secondary to Immunotherapy: A Multicenter, Controlled, Randomized, Open Trial","CHILURSO","Inclusion Criteria:\n\n* Adults ≥18 years old\n* Any type of cancer except hepatocellular or cholangiocarcinoma\n* At least one ICI injection\n* Cholestatic hepatitis Grade CTC-AE 3 or 4\n\nExclusion Criteria:\n\n* Ongoing corticosteroids treatment\n* Other causes of hepatitis\n* Cirrhosis\n* ICI for hepatocellular carcinoma or cholangiocarcinoma\n* Biliary obstruction\n* Medical contraindication to corticosteroids or UDCA\n* Mixed or hepatocellular hepatitis\n* Total bilirubin \\> 1,5 ULN, Prothrombin rate \\\u003C 70%\n* Medical contraindication to MRI or liver biopsy\n* Oher serious side effects requiring corticosteroids\n* Pregnant and breast-feeding patients\n* Patients under articles L1121-5 to 8 of the public health code\n* Lack of informed consent\n* Patients not affiliated with French social security system\n* Patients uncapable of understanding french","ALL","18 Years",{"count":139,"type":140},94,"ESTIMATED","INTERVENTIONAL",[143],"PHASE2","The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period.\n\nThe trial presents a detailed scientific justification for comparing UDCA to corticosteroids, describing the treatment and detailing the follow-up procedures. It hypothesizes that UDCA could be superior to corticosteroids for treating ICI-related cholestatic hepatitis, based on its established use in primary biliary cholangitis and a favorable tolerance profile compared to corticosteroids.",[146],"Immune-Mediated Cholestasis",[148,149,150,151],"DILI","Immune checkpoint inhibitors","Cancer","Cholestatic hepatitis","NOT_YET_RECRUITING","2026-06-17",{"date":155,"type":156},"2026-06-18","ACTUAL",{"date":158,"type":140},"2026-12",{"date":160,"type":140},"2029-08",{"name":5,"class":6},6]